Qiagen: Expect acceleration in H2 to reach FY guidance, 2014 will benefit from efficiency plan

BUY, Fair Value EUR17 (+9%)

News published on August Thursday 1, 2013
Share on

Following Q2 results that were reassuring on sales performance but slightly disappointing in terms of margins, the tone was reassuring during the conference call. Management is expecting a pick-up in H2 both in top-line growth and profitability. Molecular Diagnostics should continue with steady growth (BGe FY13: 7.5% CER) despite continuous pressure on HPV. We continue to see QuantiFeron-TB, Personalized Healthcare and QiaSymphony delivering strong double-digit growth. Other business divisions should benefit from more favourable base effects in H2 as well as a slight rebound following a weak Q1. In terms of margins, management confirmed its target to reach a 28% adjusted EBIT margin as well as positive effects from the efficiency plan in the mid-term. Finally, we are looking forward for more quantitative details on the next-gen sequencing opportunity.

Full report available to subscribers
Please contact marketing@bryangarnier.fr  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities